Evidence map›Paper›PMID 38289080›Full record

ArticleAntimicrobial agents and chemotherapy2024

Type I BREX system defends against antibiotic-resistant plasmids in

Xiaoying Jiang, Dan Li, Zhewei Sun, Yanyan Lu, Pei Li, Wanzhen Li, Dongliang Wang, Lianhua Wei, Xiaogang Xu, Yuan Yuan and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Xiaoying Jiang *Institute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Dan Li *Institute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Zhewei SunInstitute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Yanyan LuInstitute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Pei LiInstitute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Wanzhen LiInstitute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Dongliang WangInstitute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Lianhua WeiClinical Laboratory Center, Gansu Provincial Hospital, Lanzhou, Gansu, China.
Xiaogang XuInstitute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
Yuan YuanDepartment of Critical Care Medicine, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Minggui WangInstitute of Antibiotics, Huashan Hospital, Fudan University, Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.ORCID 0000-0001-7682-5859
Fudan University · CNGansu Provincial Hospital · CNShanghai University of Traditional Chinese Medicine · CN

Funding

MOST | National Natural Science Foundation of China (NSFC) 81991531
6 · The paper itself

Abstract

The Bacteriophage Exclusion (BREX) system is a novel antiphage defense system identified in

Indexed as

BacteriophagesEscherichia coli InfectionsAnti-Bacterial Agentsbeta-LactamasesEscherichia coliHumansMicrobial Sensitivity TestsPlasmidsAnti-Bacterial Agentsbeta-LactamasesBREX systemcarbapenem resistanceEscherichia coliplasmids

Identifiers

PMID38289080
PMCPMC10916371
OpenAlexW4391349047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.